Manojkumar Bupathi, MD, MS

home / authors / manojkumar-bupathi-md-ms

Articles

Manojkumar Bupathi, MD, MS

Dr Bupathi on Updates in the Second-Line Management of Advanced RCC

Manojkumar Bupathi, MD, MS
January 17th 2024

Manojkumar Bupathi, MD, MS, discusses updates in the second-line management of metastatic renal cell carcinoma and anticipated research in this space.

Read More

Manojkumar Bupathi, MD, MS

Dr Bupathi on Treating Patients With RCC in Community vs Academic Settings

Manojkumar Bupathi, MD, MS
November 28th 2023

Manojkumar Bupathi, MD, MS, discusses treating patients with renal cell carcinoma in community vs academic settings.

Read More

Manojkumar Bupathi, MD, MS

Dr. Bupathi on the Evolving Treatment Landscape of Bladder Cancer

Manojkumar Bupathi, MD, MS
December 3rd 2021

Manojkumar Bupathi, MD, MS, discusses the evolving treatment landscape of bladder cancer.

Read More

Manojkumar Bupathi, MD, MS

Dr. Bupathi on Considerations for Second-Line Sequencing in RCC

Manojkumar Bupathi, MD, MS
November 23rd 2021

Manojkumar Bupathi, MD, MS, discusses considerations for second-line treatment sequencing in clear cell renal cell carcinoma.

Read More

Manojkumar Bupathi, MD, MS

Dr. Bupathi on First-Line Treatment Options for Clear Cell RCC

Manojkumar Bupathi, MD, MS
November 16th 2021

Manojkumar Bupathi, MD, MS, discusses the improvement in first-line treatment options for patients with clear cell renal cell carcinoma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data